1-4 of 4
Qiang Guo
Close
Sort by
Journal Articles

A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

Huilai Zhang, Liping Su, Lihong Liu, Ou Bai, Zheng Song, Zhiqiang Zhao, Cuiying He, Qiang Guo, Xianhuo Wang, Wei Li, Lihua Qiu, Lanfang Li, Shiyong Zhou, Yue Fei, Xiaohui Wang, Bin Meng
Journal: Blood
Blood (2023) 142 (Supplement 1): 736.
https://doi.org/10.1182/blood-2023-178509
Published: 2023
Journal Articles

A Simple Risk-Scoring Model for Estimating the Prognostic Impact of 1q Gain in Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, Peiyu Yang, Haimin Chen, Xinyue Liang, Weiling Xu, Shanshan Yu, Wenyang Huang, Xingchen Yi, Qiang Guo, Mengru Tian, Tingting Yue, Mengyao Li, Yingjie Zhang, Mengxue Zhang, Yurong Yan, Zhongli Hu, Shaji K Kumar, Fan Zhou, Yun Dai
Journal: Blood
Blood (2022) 140 (Supplement 1): 4360–4361.
https://doi.org/10.1182/blood-2022-168602
Published: 2022
Journal Articles

Chidamide Maintenance Therapy after Induction or Salvage Treatment in Patients with Peripheral T-Cell Lymphoma Ineligible for Autologous Stem Cell Transplantation

Wei Guo, Yangzhi Zhao, Xingtong Wang, Jia Li, Qiang Guo, Junna Li, Ken H. Young, Ou Bai
Journal: Blood
Blood (2021) 138 (Supplement 1): 2442.
https://doi.org/10.1182/blood-2021-152164
Published: 2021
Journal Articles

The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone Acetate in Peripheral T Cell Lymphomas: A Real-World, Retrospective Case Series from China

Wei Guo, Xiaomeng Feng, Yinping Wang, Jia Li, Yangzhi Zhao, Limei Qu, Xu Yan, Junna Li, Qiang Guo, Ken H. Young, Ou Bai
Journal: Blood
Blood (2021) 138 (Supplement 1): 4563.
https://doi.org/10.1182/blood-2021-147695
Published: 2021